^
    Back
    Association details:
    Biomarker:BAP1 deletion
    Cancer:Mesothelioma
    Drug Class:FGFR inhibitor +
    EZH2 inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    Cancer Res Commun
    Title:

    Combined inhibition of EZH2 and FGFR is synergistic in BAP1- deficient malignant mesothelioma

    Published date:
    06/12/2023
    Excerpt:
    In this study, we investigated the synergistic potential of combining EZH2 inhibition together with FGFR inhibition for treatment of BAP1-deficient malignancies. The efficacy of the combination was evaluated using human and murine preclinical models of mesothelioma and uveal melanoma in vitro. The efficacy of the combination was further validated in vivo by using BAP1-deficient mesothelioma xenografts and autochthonous mouse models.
    DOI:
    10.1158/2767-9764.CRC-23-0276